XML 67 R52.htm IDEA: XBRL DOCUMENT
v3.3.1.900

Major Customers and Concentration of Credit Risk (Details) - USD ($) | 12 Months Ended
--- | ---
Dec. 31, 2015 | Dec. 31, 2014 | Dec. 31, 2013
Concentration Risk [Line Items] |  |  |
Revenue | $ 40,572,111 | $ 10,456,766 | $ 13,467,346
Revenue | Customer Concentration Risk |  |  |
Concentration Risk [Line Items] |  |  |
Concentration risk, percentage | 100.00% | 100.00% | 100.00%
MedImmune |  |  |
Concentration Risk [Line Items] |  |  |
Revenue | $ 16,037,731 | $ 0 | $ 0
Accounts receivable | $ 1,500,000 |  |
MedImmune | Revenue | Customer Concentration Risk |  |  |
Concentration Risk [Line Items] |  |  |
Concentration risk, percentage | 40.00% | 0.00% | 0.00%
MedImmune | Accounts Receivable | Customer Concentration Risk |  |  |
Concentration Risk [Line Items] |  |  |
Concentration risk, percentage | 20.00% |  |
DARPA |  |  |
Concentration Risk [Line Items] |  |  |
Revenue | $ 11,582,623 | $ 123,605 | $ 0
Accounts receivable | $ 4,000,000 |  |
DARPA | Revenue | Customer Concentration Risk |  |  |
Concentration Risk [Line Items] |  |  |
Concentration risk, percentage | 28.00% | 1.00% | 0.00%
DARPA | Accounts Receivable | Customer Concentration Risk |  |  |
Concentration Risk [Line Items] |  |  |
Concentration risk, percentage | 54.00% |  |
Roche |  |  |
Concentration Risk [Line Items] |  |  |
Revenue | $ 10,778,688 | $ 7,357,346 | $ 9,181,759
Accounts receivable | $ 1,600,000 | $ 2,300,000 |
Roche | Revenue | Customer Concentration Risk |  |  |
Concentration Risk [Line Items] |  |  |
Concentration risk, percentage | 27.00% | 70.00% | 68.00%
Roche | Accounts Receivable | Customer Concentration Risk |  |  |
Concentration Risk [Line Items] |  |  |
Concentration risk, percentage | 22.00% | 82.00% |
NIAID |  |  |
Concentration Risk [Line Items] |  |  |
Revenue | $ 901,475 | $ 1,229,084 | $ 2,090,939
Accounts receivable |  | $ 190,000 |
NIAID | Revenue | Customer Concentration Risk |  |  |
Concentration Risk [Line Items] |  |  |
Concentration risk, percentage | 2.00% | 12.00% | 16.00%
NIAID | Accounts Receivable | Customer Concentration Risk |  |  |
Concentration Risk [Line Items] |  |  |
Concentration risk, percentage |  | 7.00% |
GeneOne (affiliated entity) |  |  |
Concentration Risk [Line Items] |  |  |
Revenue | $ 450,000 | $ 479,464 | $ 425,000
GeneOne (affiliated entity) | Revenue | Customer Concentration Risk |  |  |
Concentration Risk [Line Items] |  |  |
Concentration risk, percentage | 1.00% | 5.00% | 3.00%
All other |  |  |
Concentration Risk [Line Items] |  |  |
Revenue | $ 821,594 | $ 1,267,267 | $ 1,769,648
All other | Revenue | Customer Concentration Risk |  |  |
Concentration Risk [Line Items] |  |  |
Concentration risk, percentage | 2.00% | 12.00% | 13.00%

X
- Definition For an unclassified balance sheet, the amount due from customers or clients for goods or services that have been delivered or sold in the normal course of business, reduced to their estimated net realizable fair value by an allowance established by the entity of the amount it deems uncertain of collection. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 942 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.9-03.9) -URI http://asc.fasb.org/extlink&oid=6876686&loc=d3e534808-122878 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 944 -SubTopic 210 -Section S99 -Paragraph 1 -Subparagraph (SX 210.7-03.5) -URI http://asc.fasb.org/extlink&oid=6879938&loc=d3e572229-122910 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 02 -Paragraph 3 -Article 5 + Details
Name: | us-gaap_AccountsReceivableNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_ConcentrationRiskLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 18 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6351-108592 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13531-108611 Reference 3: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 275 -SubTopic 10 -Section 50 -Paragraph 20 -URI http://asc.fasb.org/extlink&oid=6927468&loc=d3e6404-108592 Reference 4: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 825 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI http://asc.fasb.org/extlink&oid=35750535&loc=d3e13537-108611 + Details
Name: | us-gaap_ConcentrationRiskPercentage1
Namespace Prefix: | us-gaap_
Data Type: | num:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Total revenue from sale of goods and services rendered during the reporting period, in the normal course of business, reduced by sales returns and allowances, and sales discounts. + References Reference 1: http://www.xbrl.org/2003/role/presentationRef -Publisher FASB -Name Accounting Standards Codification -Topic 225 -SubTopic 10 -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.1) -URI http://asc.fasb.org/extlink&oid=26872669&loc=d3e20235-122688 Reference 2: http://www.xbrl.org/2003/role/presentationRef -Publisher SEC -Name Regulation S-X (SX) -Number 210 -Section 03 -Paragraph 1 -Article 5 + Details
Name: | us-gaap_SalesRevenueNet
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=ino_RevenueMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MajorCustomersAxis=ino_MedImmuneMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MajorCustomersAxis=ino_DefenseAdvancedResearchProjectsAgencyDARPAMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MajorCustomersAxis=ino_HoffmanLaRocheMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MajorCustomersAxis=ino_NiaidMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MajorCustomersAxis=ino_GeneOneLifeSciencesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_MajorCustomersAxis=ino_AllOtherCustomersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |